NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, a law firm focused on investor rights, is looking into whether the cash sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share is fair for its shareholders. The firm invites Intra-Cellular shareholders to click here for more information about their legal rights and options, or to reach out to Daniel Sadeh or Zachary Halper at (212) 763-0060 or via email at [email protected] or [email protected]. The investigation is ongoing.
Intra-Cellular Therapies (ITCI) reported a quarterly loss of $0.16 per share, which is worse than the Zacks Consensus Estimate of a $0.05 loss. This is an improvement compared to a loss of $0.30 per share from the same period last year.
In the fourth quarter of 2024, CAPLYTA's net product sales reached $199.2 million, which is a 51% rise compared to the same time in 2023.
Intra-Cellular (ITCI) saw an increase in its share price during the last trading session, with higher-than-normal trading volume. However, the recent changes in earnings estimates for the stock do not indicate that this upward trend will continue in the future.
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is looking into Intra-Cellular Therapies (Nasdaq: ITCI) for potential breaches of fiduciary duty and legal violations related to its deal with Johnson & Johnson. To find out how to participate in our investigation and get more details, click here or reach us at [email protected] or call toll-free: 866-264-3995. There is no cost or obligation involved. In this deal, Intra-Cellular Therapies shareholders will receive just $132.00 per share in cash.
Intra-Cellular Therapies (ITCI) saw its shares jump 35% in premarket trading on Monday after Johnson & Johnson (JNJ) announced plans to buy the biopharmaceutical firm for about $14.6 billion.
The acquisition includes CAPLYTA® (lumateperone), which is the first and only treatment approved by the U.S. FDA for bipolar I and II depression, both as a standalone therapy and in combination with other treatments. It is also approved for treating schizophrenia in adults.
According to Bloomberg News, Johnson & Johnson is considering making an offer to buy Intra-Cellular Therapies Inc, a company that specializes in biopharmaceuticals. This information comes from sources who are knowledgeable about the situation.
CAPLYTA experienced impressive revenue growth, reaching $125.8 million in net product revenues for Q3 2024, marking a 39% increase compared to the previous year. There is a chance for even higher revenue if CAPLYTA is approved as an additional treatment for major depressive disorder, which is a significant area of need. Additionally, Lenrispodun, a PDE inhibitor, is currently in a phase 2 trial for Parkinson's Disease, with results expected by late 2025 or early 2026, presenting another major opportunity.
Intra-Cellular has filed a supplemental New Drug Application (sNDA) with the FDA to expand the use of Caplyta for treating Major Depressive Disorder (MDD) in adults, specifically as an additional treatment alongside antidepressants.